Darío Donoso-Meneses, Cristina Padilla, María José Moya-Guzmán, Maria-Luisa Alegre & Karina Pino-Lagos — Frontiers in Immunology, 2024
This mini-review explores the emerging role of tryptophan (Trp) metabolism in regulating immune responses and influencing transplantation outcomes. Achieving long-term graft tolerance without lifelong immunosuppressive therapy remains a major challenge in transplantation. The authors highlight growing evidence that metabolites generated from tryptophan by both host cells and the intestinal microbiota can modulate alloimmune responses and may therefore provide new therapeutic targets for promoting graft survival.
Tryptophan is metabolized through three principal pathways: the kynurenine (KYN), serotonin, and microbiota-dependent indole pathways. The kynurenine pathway accounts for most Trp metabolism and is closely connected to immune regulation through enzymes such as indoleamine 2,3-dioxygenase (IDO). IDO activity and metabolites including KYN and kynurenic acid can suppress inflammatory responses, influence T-cell differentiation and promote regulatory T-cell (Treg) activity. A central mediator is the aryl hydrocarbon receptor (AhR), whose activation can influence the balance between pro-inflammatory Th17 cells and immunosuppressive Tregs.
The review gives particular attention to the gut microbiota, which converts tryptophan into indole derivatives with important immunoregulatory properties. These metabolites can activate AhR and promote anti-inflammatory pathways involving cytokines such as IL-10 and IL-22. As illustrated in the paper’s figures, this creates a complex interaction between diet, intestinal microorganisms, tryptophan metabolism and immune cells that may ultimately affect systemic immune responses.
Evidence from transplantation models supports the relevance of these pathways. In solid organ transplantation, several tryptophan metabolites have been associated with prolonged graft survival and reduced rejection. Experimental manipulation of IDO and AhR signaling has produced both tolerogenic and pro-inflammatory effects, however, demonstrating that outcomes depend strongly on the specific metabolite, receptor ligand, dose and cellular context.
Tryptophan metabolism also appears important in hematopoietic stem cell transplantation (HSCT). Changes in circulating Trp, kynurenines and microbiota-derived indoles have been associated with inflammation and graft-versus-host disease (GvHD). Experimental studies suggest that certain bacterial indoles can improve intestinal homeostasis and reduce GvHD, while clinical studies are beginning to investigate dietary interventions designed to modify microbiota metabolism.
In kidney transplantation, metabolites such as indoxyl sulfate and indole acetic acid decrease following transplantation and may reflect changes in kidney function. Particularly interesting is the identification of kynurenic acid and tryptamine in kidney recipients who discontinued immunosuppressive treatment and developed spontaneous operational tolerance, suggesting a possible connection between microbiota composition, tryptophan metabolism and long-term graft acceptance.
Overall, the review presents tryptophan metabolism as an important link between the gut microbiota, immune regulation and transplant outcomes. Although current evidence points to promising immunoregulatory mechanisms and potential therapeutic targets, the authors emphasize that further human studies are needed to determine how specific metabolites and metabolic pathways influence graft acceptance or rejection. A deeper understanding of these mechanisms could ultimately contribute to new strategies for preventing allograft rejection and promoting transplant tolerance.